US Edition2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
- Innovent presents preclinical data on novel oncology molecules at the AACR meeting in Chicago, Illinois.
- The biopharmaceutical company focuses on developing innovative therapies through scientific advancements.
- The presented data covers bispecific antibodies, tri-specific antibodies, and antibody-drug conjugates.
- Innovent reports 15 marketed products and 15 molecules in early clinical development.
- Preclinical findings show expanding research capabilities and support future clinical development.
39 Articles
39 Articles
Helena Independent Record
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…
Innovent Showcases Breakthrough Preclinical Data on Novel Antibodies at AACR 2025
SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as b…
Coverage Details
Bias Distribution
- 83% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
